Meeting
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
Authors
Shakeel Modak
Memorial Sloan Kettering Cancer Center, New York, NY
Shakeel Modak , Brian H. Kushner , Audrey Mauguen , Alicia Castañeda , Amalia Varo , Maite Gorostegui , Juan Pablo Muñoz , Vicente Santa-Maria , Ellen M. Basu , Fiorella Iglesias Cardenas , Neeta Pandit-Taskar , Nai-Kong V. Cheung , Jaume Mora
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10028)
DOI
10.1200/JCO.2022.40.16_suppl.10028
Abstract #
10028
Poster Bd #
243
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.
First Author: Jaume Mora
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan
Poster
2016 ASCO Annual Meeting
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
First Author: Steven G. DuBois
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa